Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Takeda Pharmaceutical Co's other long-term liabilities for the quarter that ended in Jun. 2026 was $4,671 Mil.
Takeda Pharmaceutical Co's quarterly other long-term liabilities
declined
from Dec. 2025 ($4,484 Mil) to Mar. 2026 ($4,466 Mil) but then
increased
from Mar. 2026 ($4,466 Mil) to Jun. 2026 ($4,671 Mil).
Takeda Pharmaceutical Co's annual other long-term liabilities
declined
from Mar. 2024 ($5,227 Mil) to Mar. 2025 ($4,488 Mil) and
declined
from Mar. 2025 ($4,488 Mil) to Mar. 2026 ($4,466 Mil).
Takeda Pharmaceutical Co Other Long-Term Liabilities Related Terms
Takeda Pharmaceutical Co Other Long-Term Liabilities Historical Data
* Premium members only.
The historical data trend for Takeda Pharmaceutical Co's Other Long-Term Liabilities can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Takeda Pharmaceutical Co Other Long-Term Liabilities Chart
Takeda Pharmaceutical Co Other Long-Term Liabilities Calculation
Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.
What does a Other Long-Term Liabilities of $4,671 Mil mean?
Takeda Pharmaceutical Co (TAK) has a Other Long-Term Liabilities of $4,671 Mil as of Jun. 2026. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Takeda Pharmaceutical Co and its competitors.
Is Takeda Pharmaceutical Co's Other Long-Term Liabilities too high?
Takeda Pharmaceutical Co's current Other Long-Term Liabilities is $4,671 Mil. Overall, Takeda Pharmaceutical Co has a GF Score™ of 76/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Takeda Pharmaceutical Co's Other Long-Term Liabilities compare to ZTS?
Takeda Pharmaceutical Co's Other Long-Term Liabilities of $4,671 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Drug Manufacturers company?
A good Other Long-Term Liabilities depends on the Drug Manufacturers industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Takeda Pharmaceutical Co and its competitors. Takeda Pharmaceutical Co's current Other Long-Term Liabilities is $4,671 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Takeda Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Takeda Pharmaceutical Co (TAK) is currently considered Modestly Overvalued. The stock's GF Value™ is $14.22, compared to a current price of $18.23 — trading 28.2% above its estimated fair value. The current Other Long-Term Liabilities is $4,671 Mil. Takeda Pharmaceutical Co's overall GF Score™ is 76/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Takeda Pharmaceutical Co (TAK), the current Other Long-Term Liabilities is $4,671 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Takeda Pharmaceutical Co (TAK) Overvalued in 2026?
Based on GuruFocus' analysis, Takeda Pharmaceutical Co stock appears to be overvalued.
The current stock price of $18.23 is trading 28.2% above its estimated GF Value™ of $14.22.
GuruFocus considers Takeda Pharmaceutical Co to be Modestly Overvalued.
Key valuation signals for TAK:
Other Long-Term Liabilities: $4,671 Mil
GF Value™: $14.22 vs. price of $18.23 (28.2% above fair value)
No single metric tells the full story. See the TAK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.
76GF Score
Get the complete analysis for TAK
Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TAK has been successfully added to your 
